Rare disease trials can’t find enough patients. It’s forcing the FDA to rethink its approach

When Hannah Sames was 4 years old, she was diagnosed with an ultra-rare genetic condition called giant axonal neuropathy. She’s 18 now, and her doctors expected long ago that she would be quadriplegic, and consigned to an early death.

Instead, she can stand, albeit with help. “Even with her physical...

Click to view original post